XOMA Provides Update on Gevokizumab Proof-of-Concept Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
XOMA Ltd (XOMA) Posts Q4 GAAP Loss of 55c/Share
March 4, 2014 5:00 PM ESTXOMA Ltd (NASDAQ: XOMA) reported Q4 EPS of ($0.55), which may not compare with the analyst estimate of ($0.19). Revenue for the quarter came in at $8.45 million versus the consensus estimate of $7.92 million.
Of the $0.55 per share loss, $35.3 million, or $0.37 per share, was related directly to the... More
XOMA (XOMA) Will Not Pursue Gevokizumab Development for EOA Indication
March 4, 2014 4:39 PM ESTXOMA (Nasdaq: XOMA) provided an update on its gevokizumab development program. Based on results from the Company's Phase 2 program in patients with erosive osteoarthritis of the hand (EOA), XOMA does not intend to launch pivotal development for the broad EOA indication. The Company will conduct a review of the full dataset to determine if there is a segment of the patient population that best responds to gevokizumab therapy prior to initiating any potential additional clinical studies in this indication. Gevokizumab appeared to be well tolerated, and the most common adverse events were comparable between... More
